Efficacy and safety results from ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: Update after 48 weeks Meeting Abstract
| Authors: | Mauro, M. J.; Minami, Y.; Rea, D.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A. G.; Kim, D. W.; Apperley, J. F.; Cortes, J. E.; Abdo, A. N. R.; Fogliatto, L.; Kim, D. D. H.; le Coutre, P. D.; Saussele, S.; Annunziata, M.; Hughes, T. P.; Chaudhri, N. A.; Chee, L. C. Y.; Gutierrez, V. G.; Sasaki, K.; Kapoor, S.; Allepuz, A.; Quenet, S.; Bédoucha, V.; Boquimpani, C. |
| Abstract Title: | Efficacy and safety results from ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: Update after 48 weeks |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398801087 |
| DOI: | 10.1182/blood-2021-152561 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 310 -- Hybrid meeting, also took place online -- Source: Wos |
